Skip to content

Drug interactions

Lorlatinib + Pirtobrutinib

Severity: Major

Lorlatinib and Pirtobrutinib: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Pirtobrutinib is metabolized by CYP3A4, and lorlatinib induces this enzyme. Reduced pirtobrutinib exposure may impair control of the underlying B-cell malignancy.

What this interaction means in plain words

Lorlatinib and Pirtobrutinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Lorlatinib belongs to Oncology; Pirtobrutinib belongs to Oncology.

Evidence level: Moderate

Why it happens

Lorlatinib induces CYP3A4, increasing pirtobrutinib clearance.

What to do

Avoid coadministration. If unavoidable, increase the pirtobrutinib dose according to product labeling and monitor disease response.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Pirtobrutinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Lorlatinib with Pirtobrutinib?

MediHelp rates the interaction as major. Lorlatinib and Pirtobrutinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Pirtobrutinib is metabolized by CYP3A4, and lorlatinib induces this enzyme. Reduced pirtobrutinib exposure may impair control of the underlying B-cell malignancy.

How serious is the interaction between Lorlatinib and Pirtobrutinib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid coadministration. If unavoidable, increase the pirtobrutinib dose according to product labeling and monitor disease response.

What other medicines interact with Lorlatinib?

MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in